CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10165|
|Strength||1 mg, 2 mg, 3 mg & 4 mg|
|Indication||Multiple Myeloma (second-line or beyond)|
|Funding Request||Pomalidomide in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||July 2, 2019|
|Submission Date||March 15, 2019|
|Submission Deemed Complete||March 29, 2019|
|Submission Type||New Indication|
|Stakeholder Input Deadline ‡||March 29, 2019|
|Check-point meeting||June 5, 2019|
|pERC Meeting||August 15, 2019|
|Initial Recommendation Issued||August 29, 2019|
|Feedback Deadline ‡||September 13, 2019|
|Final Recommendation Issued||September 18, 2019|
|Notification to Implement Issued||October 3, 2019|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.